TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00931073
Drug: Dimebon + Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
Study: NCT00931073
Drug: Dimebon + Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
Study: NCT02433353
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serotonin norepinephrine reuptake inhibitor
Study: NCT02498665
Drug: DSP-7888 Dosing Emulsion
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
Study: NCT04655586
Drug: rNAPc2
Normalized name: rNAPc2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two dose levels of rNAPc2
Study: NCT01287585
Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
Normalized name: PEG-20 stearate
DrugBank: Pegargiminase (DB06592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
Study: NCT00932893
Drug: PF-02341066
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-02341066, 250 mg BID will be administered orally on a continuous schedule
Study: NCT00932893
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
Study: NCT00932893
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
Study: NCT04209660
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
Study: NCT04209660
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
Study: NCT01490177
Drug: Food proteins
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of Food proteins
Study: NCT03045484
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
Study: NCT01330446
Drug: Armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
Study: NCT01464697
Drug: Oral micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
Study: NCT03537690
Drug: PEOX-based Polymer Encapsulated Paclitaxel FID-007
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03133481
Drug: Femoral Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional technique
Study: NCT03431077
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
Study: NCT00102037
Drug: eptacog alfa (activated)
Normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01050062
Drug: Telmisartan 80mg
Normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination tablet
Study: NCT01050062
Drug: Telmisartan 40mg
Normalized name: TELMISARTAN 40MG TAB
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination tablet
Study: NCT03043365
Drug: control fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, 3 times a day after meals
Study: NCT03043365
Drug: LCMUFA-rich saury oil
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, 3 times a day after meals
Study: NCT01184989
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily approved dose by EMEA and Health Canada
Study: NCT01819961
Drug: MCT/LCT and fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03920605
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
Study: NCT03920605
Drug: Peginterferon Alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
Study: NCT03920605
Drug: Peginterferon Alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
Study: NCT03333369
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02410369
Drug: S-588410
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
Study: NCT00414622
Drug: DMXB-A
Normalized name: DMXB-A
DrugBank: GTS-21 (DB05708)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01611077
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
Study: NCT01611077
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Switch to olmesartan 40 mg tablets once daily for 42 days,
Study: NCT01611077
Drug: Olmesartan/amlodipine
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
Study: NCT01579201
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
Study: NCT00846612
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
Study: NCT00846612
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
Study: NCT02584569
Drug: TAK-915
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-915 oral suspension
Study: NCT03881163
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
Study: NCT03396471
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
Study: NCT06094712
Drug: CORT125134
Normalized name: CORT125134
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT125134 150-mg capsule
Study: NCT02796144
Drug: Lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Max dose of 10 mg BID
Study: NCT02796144
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Max dose of 1,000 mg BID
Study: NCT02061137
Drug: fingolimod (FTY720)
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
Study: NCT03971617
Drug: Hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: each hydrogen tablet contains 80mg magnesium
Study: NCT01868581
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
Study: NCT01868581
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
Study: NCT00184054
Drug: Arsenic Trioxide (ATO)
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic Trioxide .25 mg/kg/day
Study: NCT04318223
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
Study: NCT01169870
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00364039
Drug: AV650
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02221739
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00744367
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: \>1500 mg/day or maximum tolerated dose (MTD)
Study: NCT00744367
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \>= 30 mg/day
Study: NCT00744367
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sc once weekly;
Study: NCT00744367
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
Study: NCT01851473
Drug: cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg IV on days 1, 5, and 10
Study: NCT01851473
Drug: quinine
Normalized name: Quinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg orally on days 7-10
Study: NCT01851473
Drug: acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg orally on days 2-5
Study: NCT02231203
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Study: NCT01656616
Drug: Cyanide antidote administration
Normalized name: cyanide
DrugBank: N-Butyl Isocyanide (DB01826)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01188798
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
Study: NCT02795767
Drug: Emicizumab
Normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emicizumab will be administered as per the schedule specified in the respective arm.
Study: NCT00754767
Drug: L-carnitine L-tartrate
Normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00611130
Drug: vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets twice a day for 9 weeks
Study: NCT03046238
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
Study: NCT04722133
Drug: HERZUMA+mFOLFOX
Normalized name: Herzuma
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
Study: NCT00319618
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00319618
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02596880
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
Study: NCT02596880
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
Study: NCT02596880
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
Study: NCT01784549
Drug: Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00153166
Drug: atorvastatin and pioglitazone
Normalized name: glimepiride and pioglitazone
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
Study: NCT00153166
Drug: atorvastatin/placebo
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 80 mg orally once daily and matching placebo orally twice daily
Study: NCT00153166
Drug: pioglitazone/placebo
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pioglitazone 30 mg orally once daily and matching placebo orally once daily
Study: NCT00165568
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01845077
Drug: 2x500 mg Metformin (Glumetza)
Normalized name: metformin hydrochloride 1000 MG [Glumetza]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 tablets
Study: NCT01845077
Drug: 5 mg Linagliptin/1000 mg Metformin FDC
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FDC tablet
Study: NCT01845077
Drug: 5 mg Linagliptin (Tradjenta)
Normalized name: linagliptin 5 MG
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet
Study: NCT01845077
Drug: 3x500 mg Metformin (Glumetza)
Normalized name: metformin hydrochloride 1000 MG [Glumetza]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 tablets
Study: NCT01845077
Drug: 2 x 500 mg Metformin (Glumetza)
Normalized name: metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 tablets
Study: NCT01845077
Drug: 5 mg Linagliptin/1000mg Metformin FDC
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FDC Tablet
Study: NCT01845077
Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 FDC tablets
Study: NCT00953121
Drug: bevacizumab and CPT-11 and Carboplatin
Normalized name: Carboplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
Study: NCT00982020
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
Study: NCT00761501
Drug: PN400
Normalized name: Pantoprazole sodium
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT03618225
Drug: Oral Duloxetine 60mg
Normalized name: duloxetine 60 MG
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
Study: NCT04111822
Drug: red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
Study: NCT04111822
Drug: on crystalloid fluid and Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
Study: NCT02095730
Drug: Epithelium-On Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
Study: NCT02095730
Drug: Epithelium-Off Riboflavin
Normalized name: Off! Explore
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin 0.1% Phosphate Sodium solution
Study: NCT00125203
Drug: Botulinum toxin type B (Myobloc)
Normalized name: botulinum toxin type B
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02209597
Drug: Bupropion XL 300
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics).
Study: NCT02436798
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will be receiving treatment with ondansetron as part of standard care.
Study: NCT02262130
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01595646
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline, administered intranasally twice per day for a 16 week duration
Study: NCT01595646
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
Study: NCT01595646
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)